Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects

被引:69
|
作者
Smith, RJ
Wahl, LM [1 ]
机构
[1] Univ Western Ontario, Dept Math Appl, London, ON N6A 5B7, Canada
[2] Univ Illinois, Dept Math, Urbana, IL 61802 USA
[3] Univ Illinois, Dept Vet Pathobiol, Urbana, IL 61802 USA
关键词
D O I
10.1016/j.bulm.2004.10.004
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We consider an SIR-type model of immunological behaviour for HIV dynamics, including the effects of reverse transcriptase inhibitors and other drugs which prevent cellular infection. We use impulsive differential equations to model drug behaviour. We classify different regimes according to whether the drug efficacy is negligible, intermediate or high. We consider two strains of the virus: a wild-type strain that can be controlled by both intermediate and high drug concentrations, and a mutant strain that can only be controlled by high drug concentrations. Drug regimes may take trajectories through one, two or all three regimes, depending on the dosage and the dosing schedule. We demonstrate that drug resistance arises at both intermediate and high drug levels. At low drug levels resistance does not emerge, but the total T cell count is proven to be significantly lower than in the disease-free state. At intermediate drug levels, drug resistance is guaranteed to emerge. At high drug levels, either the drug-resistant strain will dominate or, in the absence of longer-lived reservoirs of infected cells, both viral sub-populations will be cleared. In the latter case the immune system is maintained by a population of T cells which have absorbed sufficient quantities of the drug to prevent infection by even the drug-resistant strain. We provide estimates of a range of dosages and dosing schedules which would, if physiologically tolerable, theoretically eliminate free virus in this system. Our results predict that to control viral load, decreasing the interval between doses is more effective than increasing the dose. (c) 2004 Society for Mathematical Biology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:783 / 813
页数:31
相关论文
共 50 条
  • [31] HIV-1 CHEMOTHERAPY AND DRUG-RESISTANCE
    DAQUILA, RT
    CLINICAL AND DIAGNOSTIC VIROLOGY, 1995, 3 (04): : 299 - 316
  • [32] HIV-1: Gambling on the evolution of drug resistance?
    Andrew J. Leigh Brown
    Douglas D. Richman
    Nature Medicine, 1997, 3 : 268 - 271
  • [33] HIV-1: Gambling on the evolution of drug resistance?
    Brown, AJL
    Richman, DD
    NATURE MEDICINE, 1997, 3 (03) : 268 - 271
  • [34] ON THE MECHANISMS OF DRUG RESISTANCE IN HIV-1 RT
    Sharma, B.
    SEXUALLY TRANSMITTED INFECTIONS, 2013, 89 : A78 - A78
  • [35] Pretreatment HIV-1 drug resistance in Africa
    Hamers, Raph L.
    Kityo, Cissy
    Sigaloff, Kim C. E.
    de Wit, Tobias F. Rinke
    LANCET INFECTIOUS DISEASES, 2013, 13 (06): : 476 - 476
  • [36] Recent trends in HIV-1 drug resistance
    Siliciano, Janet D.
    Siliciano, Robert F.
    CURRENT OPINION IN VIROLOGY, 2013, 3 (05) : 487 - 494
  • [37] Primary HIV-1 drug resistance in Brazil
    Soares, MA
    Brindeiro, RM
    Tanuri, A
    AIDS, 2004, 18 : S9 - S13
  • [38] A model of directional selection applied to the evolution of drug resistance in HIV-1
    Seoighe, Cathal
    Ketwaroo, Farahnaz
    Pillay, Visva
    Scheffler, Konrad
    Wood, Natasha
    Duffet, Rodger
    Zvelebil, Marketa
    Martinson, Neil
    McIntyre, James
    Morris, Lynn
    Hide, Winston
    MOLECULAR BIOLOGY AND EVOLUTION, 2007, 24 (04) : 1025 - 1031
  • [39] Dynamics of Transmitted HIV-1 Drug Resistance - The San Francisco Model
    Abecasis, Ana B.
    Mueller, Viktor
    AIDS REVIEWS, 2010, 12 (02) : 122 - 123
  • [40] Dynamic expression of HIV-1 drug resistance mutations during acute infection
    Lipscomb, J. T.
    Owen, S. M.
    Johnson, J. A.
    ANTIVIRAL THERAPY, 2010, 15 : A47 - A47